Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02193945 · ClinicalTrials.gov registry record
A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA
A clinical trial, sponsored by ThromboGenics.
- Completed
- Registry status
- 134
- Enrollment target
NCT02193945 is a clinical trial that has completed, run by ThromboGenics. The registered enrollment target is 134 participants.
The verdict
NCT02193945 has completed, sponsored by ThromboGenics.
- COMPLETED
- Registry status
- 134 participants
- Enrollment target
Study Summary
The purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of symptomatic vitreomacular adhesion (VMA) with JETREA® (ocriplasmin), including incidence, time to onset and resolution of anatomy and symptoms.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02193945
The ClinicalTrials.gov registry entry for NCT02193945 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ThromboGenics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02193945 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02193945 about?
NCT02193945 is a clinical study titled "A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA". The purpose of this study is to retrospectively review and further characterize anatomic and symptomatic changes over six months immediately following treatment of symptomatic vitreomacular adhesion (VMA) with JETREA® (ocriplasmin), including incidence, time to onset and resolution of anatomy and sy...
What is the current status of trial NCT02193945?
This trial is currently completed. The enrollment target is 134 participants. The study started on 2014-08. Estimated completion is 2015-05.
Who is sponsoring clinical trial NCT02193945?
This trial is sponsored by ThromboGenics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.